The Food and Drug Administration has granted approval for the first flu vaccine utilizing mRNA technology. Moderna confirmed this development on Wednesday evening, marking a significant advancement in vaccine options for respiratory illnesses.
This new vaccine will be accessible to adults aged 50 and over who seek immunization against the flu. Moderna disclosed that the shot will likely be available at select retailers within the upcoming weeks.
The approval comes after discussions, including skepticism from figures like RFK Jr., regarding mRNA technology. Despite these controversies, the move forward indicates a growing acceptance and reliance on mRNA-based solutions for combating illnesses.
An image taken in 2024 at Moderna’s headquarters in Cambridge, Massachusetts, captured a researcher engaged in work related to mRNA vaccines. This image highlights the ongoing efforts in developing innovative vaccine technologies.
Strategies for Muscle Preservation on GLP-1 Medications 
Insights from a Hospital Executive’s Journey Working ER Shifts 
Biden Reflects on Memoir and Health Challenges 
Former Aide Criticizes Trump’s Advisers on Health Initiatives 
From Flight Attendant to Content Receptionist: Embracing Simplicity 
A Different Approach to Aging and Beauty